# Safety and Efficacy of Allogeneic Bone Marrow MSCs in Ankylosing Spondylitis

> **NCT07632599** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Eighth Affiliated Hospital, Sun Yat-sen University** · enrollment: 40 (estimated)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **BIOLOGICAL:** IV administration of CG-BM1
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** CG-BM1

## Key facts

- **NCT ID:** NCT07632599
- **Lead sponsor:** Eighth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632599, "Safety and Efficacy of Allogeneic Bone Marrow MSCs in Ankylosing Spondylitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07632599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*